Avid Bioservices (CDMO) Misses Q1 EPS by 1c, beats revenue, offers guidance

Avid Bioservices (NASDAQ: CDMO) reported Q1 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $37.7 million versus the consensus estimate of $37.06 million.

GUIDANCE:

Avid Bioservices sees FY 2024 revenue of $145-165 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Rivian raises 2026 delivery outlook after Q2 results top guidance